Arcutis Biotherapeutics, Inc. (ARQT) compared with its closest peers (AVIR, ESPR, ARDX, INVA, CRMD). Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Atea Pharmaceuticals, Esperion Therapeutics, Ardelyx, Innoviva, CorMedix, Ironwood Pharmaceuticals, Nature's Sunshine Products, Rigel Pharmaceuticals, Xeris Biopharma and BridgeBio Pharma share Arcutis Biotherapeutics's sub-industry, pharmaceutical makers.
| Company | Market Cap | P/E |
|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | $434.71M | -1.8 |
| Esperion Therapeutics, Inc. (ESPR) | $821.21M | -33.7 |
| Ardelyx, Inc. (ARDX) | $968.09M | -22.4 |
| Innoviva, Inc. (INVA) | $1.52B | 4.0 |
| CorMedix Inc. (CRMD) | $638.36M | 3.4 |
| Ironwood Pharmaceuticals, Inc. (IRWD) | $708.05M | 4.1 |
| Nature's Sunshine Products, Inc. (NATR) | $252.32M | 13.2 |
| Rigel Pharmaceuticals, Inc. (RIGL) | $857.22M | 13.7 |
| Xeris Biopharma Holdings, Inc. (XERS) | $1.50B | — |
| BridgeBio Pharma, Inc. (BBIO) | $15.93B | -20.2 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
ARQT overview · ARQT earnings · ARQT financials · ARQT KPIs · ARQT documents · ARQT ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.